UCI Health made a strong showing at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, with faculty and trainees contributing original research, leading key discussions, and highlighting studies with the potential to reshape cancer care. Among the standout presentations was gynecologic oncology fellow Alyssa Bujnak, MD, who shared findings from a translational analysis of the pivotal GOG-0240 trial in recurrent and metastatic cervical cancer. Conducted under the mentorship of Krishnansu Tewari, MD, the study identified microRNAs linked to overall survival and response to bevacizumab, offering new insights into personalized treatment strategies. “It’s been exciting to contribute to a project with real potential for clinical impact,” said Bujnak.

The ASCO platform also spotlighted the collaborative spirit and academic rigor of UCI’s early-career investigators. From senior leadership to fellows, the presence UCI Health had at ASCO 2025 underscores the commitment to advancing evidence-based oncology care through innovation and discovery.